Current Management of Bone Metastatic Castrate-Resistant Prostate Cancer : Panel Discussion

January 24, 2019

Daniel George is joined by a multi-specialty group of experts to discuss the latest research on CRPC with bone metastases. The conversation details the mechanism of action of Radium-223 in prostate cancer, a review of the ALSYMPCA trial and the impact of the ERA-223 trial.


Daniel George, MD is Professor of Medicine and Surgery, Divisions of Medical Oncology and Urology in the Duke University School of Medicine and leads the Duke Prostate and Urologic Cancer Center.

Charles J. Ryan, MD is the B.J. Kennedy Chair in Clinical Medical Oncology at the University of Minnesota and Director of the Division of Hematology, Oncology, and Transplantation.

Phillip J. Koo, MD is the Division Chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center

Fred Saad, MD FRCS Professor and Chief of Urology, Director of GU Oncology, Raymond Garneau Chair in Prostate Cancer, University of Montreal Hospital Centre (CHUM), Director, Prostate Cancer Research, Institut du cancer de Montréal/CRCHUM.

Joe O'Sullivan, MD, FRCR, Oncologist, Northern Ireland Cancer Center, Professor of Radiation Oncology, Queen's University Belfast